Jubilant Pharmova clears FDA inspection of Washington facilities

The inspection, which took place from September 18 to 25, covered both the allergy immunotherapy facility and the contract manufacturing facility. Shares of Jubilant Pharmova Ltd ended at ₹1,183.90, down by ₹25.75, or 2.13%, on the BSE.

Leave a Reply

Your email address will not be published. Required fields are marked *